Primary Headache Disorders
Conditions
Brief summary
This observational, case-control study will evaluate differences in serum uric acid and related hematologic and biochemical parameters between adolescents (12-18 years) with primary headache and age-/sex-matched controls without recurrent headaches or chronic medical/psychiatric disorders. Cases will meet International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria verified by a pediatric neurologist after comprehensive clinical assessment. The study will also collect sociodemographic data and anthropometrics to calculate BMI. Primary outcome is the between-group difference in serum uric acid levels at enrollment. Secondary outcomes include group differences in ferritin, creatinine, BUN, complete blood count indices (Hb, WBC, neutrophils, lymphocytes, platelets, MPV), and BMI.
Interventions
None listed
Sponsors
Konya Necmettin Erbakan Üniversitesi
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria (Cases): Adolescents aged 12-18 years presenting to pediatric neurology outpatient clinics Diagnosis of primary headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) (e.g., 1.1, 1.2, etc.) Diagnosis confirmed by a pediatric neurologist following a comprehensive clinical evaluation Sufficient cognitive ability to understand and complete study instruments * Inclusion Criteria (Controls): Adolescents aged 12-18 years presenting to general pediatric outpatient clinics No history of recurrent headaches No chronic medical or psychiatric disorders Matched with the case group for age and sex
Exclusion criteria
* History of neurological disorders other than primary headache * Previously diagnosed psychiatric conditions * Autoimmune diseases, chronic infections, severe cardiac failure, metabolic or inflammatory disorders, obesity, or significant hepatic or renal impairment * Regular use of psychotropic medications or a history of polycythemia * Use of drugs known to affect uric acid metabolism within 2-4 weeks prior to enrollment * Cognitive or developmental disabilities limiting the ability to understand or complete study instruments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum uric acid level (mg/dL) - between-group difference (Cases vs Controls) | At enrollment (single draw) | At enrollment; between-group differences. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Ferritin level (ug/L) | At enrollment (single draw) | At enrollment; between-group differences. |
| Serum Creatinine level(mg/dL) | At enrollment (single draw) | At enrollment; between-group differences. |
| Serum BUN level (mg/dL) | At enrollment (single draw) | At enrollment; between-group differences. |
| Hemoglobin (Hb) | At enrollment (single draw) | Hb (g/dL), At enrollment; between-group differences. |
| White blood cell count (WBC) | At enrollment (single draw) | WBC (×10⁹/L), At enrollment; between-group differences. |
| Neutrophil count | At enrollment (single draw) | Neutrophils (×10⁹/L), At enrollment; between-group differences. |
| Lymphocyte count | At enrollment (single draw) | Lymphocytes (×10⁹/L), At enrollment; between-group differences. |
| Platelet count | At enrollment (single draw) | Platelets (×10⁹/L), At enrollment; between-group differences. |
| Mean platelet volume (MPV) | At enrollment (single draw) | MPV (fL) - At enrollment; between-group differences. |
Contacts
CONTACTFatma SARGIN, M.D
Outcome results
None listed